Microbioz India, May 2019 edition of magazine by Microbioz India,Laboratory Equipment,Magazines,Pharma and Healthcare News,Laboratory News

34 Cover Story 14 The cover story entitled “Pharma Laboratory and Waste Management”authored by Microbioz editorial team.The cover story features Pharmaceutical laboratory wastes and their management and includes some discussion on sustainability- as more and more pharmaceutical companies launch new projects, an even greater amount of pharmaceuticals are secreted into the environment.

Featured article

The Asthma Diet: What you eat definitely makes a difference

Asthma is a chronic condition triggered by certain allergens that cause breathlessness, wheezing and coughing by affecting the lungs. This happens because when in contact with an allergen, the mucous membrane gets irritated and as a result, the airways swell up.

Lupin in alliance with Natco receives FDA approval for 26 Bosentan Tablets

Added to this, the current edition has a special featured article entitled “Element speciation using HPLC coupling – PlasmaQuant MS and PQ LC”. LC-ICP-MS and IC-ICP-MS by Analytik Jena are versatile, robust and highly sensitive methods for the determination of element species in various fields, e.g. the characterization of environmental, food and agricultural samples or consumer goods.

Mumbai, Baltimore, April 30, 2019: Lupin Limited (Lupin) in alliance with Natco Pharma (Natco) announced that it has received approval for Bosentan Tablets, 62.5 mg and 125 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Actelion Pharmaceuticals Limited’s Tracleer Tablets, 62.5 mg and 125 mg

Product Launches

Researchers identify faster, more effective drug combinations to treat tuberculosis

The edition also covers recent Pharma news articles and product launches collected from worldwide sources to update the readers with the current trends in the industry

Tuberculosis is a potentially deadly though curable disease. Each year about 10 million people develop active cases, and 1.6 million people die.

Microbioz India, May 2019

ear friends and readers, I hope you would have enjoyed reading our previous issue. Once again, I am delighted to bring to you the May 2019 edition of Microbioz India magazine, supported by the cover story entitled “Pharma Laboratory and Waste Management”authored by Microbioz editorial team. The cover story features Pharmaceutical laboratory wastes and their management and includes some discussion on sustainability- as more and more pharmaceutical companies launch new projects, an even greater amount of pharmaceuticals are secreted into the environment. However, companies are still working towards that aim. According to the statistics reported by WHO, 15 percent of the waste generated by health-care activities is considered to be hazardous: infectious, toxic, or radioactive. Added to this, the current edition has a special featured article entitled “Element speciation using HPLC coupling – PlasmaQuant MS and PQ LC”. LC-ICP-MS and IC-ICP-MS by Analytik Jena are versatile, robust and highly sensitive methods for the determination of element species in various fields, e.g. the characterization of environmental, food and agricultural samples or consumer goods. The coupling of the PlasmaQuant MS instruments and the systems of the PQ LC series offers outstanding precision and accuracy in element speciation, with well-defined and clearly separated peaks. We have the latest market research news and insightful product launches inside, collected from worldwide sources to keep you updated with what is going on in the industry. Dear friends and readers, I hope you find some value in the magazine. Also, I would like to thanks you for being together in this beautiful journey so far. We would love to have your valuable feedback and suggestions as they help us to come up with better content each time. For any further valuable addition, please write to us at editor@microbiozindia.com.

Microbioz India, May 2019

Cover Story

Pharma Laboratory and waste Management A s more and more pharmaceutical companies launch new projects, an even greater amount of pharmaceuticals are secreted into the environment. "Sustainability" has become common place in operational discussions; however, companies are still working toward that aim. According to statistics reported by WHO, 15 percent of waste generated by health-care activities is considered to be hazardous: infectious, toxic, or radioactive. In hospitals, pharmaceutical waste is generally discarded down the drain or land filled, except chemotherapy agents, which are often sent to a regulated medical waste incinerator. These practices were developed at a time when knowledge was not available about the potential adverse effects of introducing waste pharmaceuticals into the environment. Proper pharmaceutical waste management is a highly complex new frontier in environmental management for health care facilities. A hospital pharmacy generally stocks between 2,000 and 4,000 different items, each of which must be evaluated against state and federal hazardous waste regulations. Pharmacists and

nurses generally do not receive training on hazardous waste management during their academic studies, and safety and environmental services managers may not be familiar with the active ingredients and formulations of pharmaceutical products. Frequently used pharmaceuticals, such as epinephrine, warfarin, and nine chemotherapeutic agents, are regulated as hazardous waste under the Resource Conservation and Recovery Act (RCRA). Failure to comply with hazardous waste regulations by improperly managing and disposing of such waste can result in potentially serious violations and large penalties.

Pharmaceutical waste Pharmaceutical waste is probably generated thorough a good selection of activities could be a health care facility , together with however syringes, and not restricted to endovenous (IV) preparation , general combining , spills/breakage, partly used vials, syringes, and IVs, stopped , unused arrangements, unused unit dose repacks, patients personal medications what is additional, obsolete prescribed drugs.

Microbioz India, May 2019

Cover Story Social welfare ventures will generate unsafe waste from several sources,

extremely important part of the medical waste management industry. Without the proper treatment, waste that is still dangerous which is either hazardous or infectious or can end up in landfills. Microwaving Use of associate degree magnetic attraction field over the BMW incites the fluid inside the waste to waver and warmth up, obliterating the irresistible parts by conductivity. Before microwaving, BMWs need shredding to an appropriate size and humidification. Chemical disinfection Substance purification is the utilization of a fluid compound operator to wipe out the greater part of pathogenic microorganisms, except for bacterial spores, on lifeless protests or surfaces. Deep burial The deep buried ground ought to be pre- pared by digging a pit of few meters in a neighborhood that's not susceptible to certain factors, and wherever the soil is comparatively impervious, Municipal land filling method This involves transfer of shared HCWs and sterilized strong BMWs at a land-fill planned and worked to get metropolitan strong waste.

Chemical Waste Management Figure: Waste management Hierarchy in case of Medical & Healthcare watse

Together with disposal of prescribed drugs. These waste may furthermore exemplify ended prescription, patients' close to home medicines, squander materials containing overabundance drug

Pharmaceutical Waste Management and Disposable methods: Incineration Incineration could be a high-temperature oxidization method which involves burning of the waste high temperatures. These emissions embody steam, carbonic acid gas, N oxides, stuff, and harmful byproducts. Autoclave The sterilization and treatment of medical waste before itâ&#x20AC;&#x2122;s dumped as garbage is an

Cheap and easily obtained chemicals can neutralize specific drugs, particularly chemotherapeutic agents. Many are listed in the Annexes of the WHO Guidelines on the Safe Management of Wastes from Healthcare Facilities (the Blue Book). These are particularly useful for small amounts of liquid residues, for example in IV sets. Inertisation and encapsulation procedures have long been recommended by WHO in emergency situations and they are just as applicable to low resource environments. Inertisation involves taking the pills out of the packaging, mixing with liquid concrete and depositing the concrete in a landfill before it sets. Encapsulation is the practice of putting the pharmaceuticals into barrels, which are then filled with concrete and landfilled. This can be done more cheaply and quickly since the pills will not have to be taken out of the PVC blister packs they are usually supplied in. These packs are not recyclable, so no useful resources are wasted. Finally, a little known technology called alkaline hydrolysis has good potential. It is capable of breaking down animal tissues, killing pathogens

Microbioz India, May 2019

Cover Story

Figure: Categorizing Pharmaceutical and Non Pharmaceutical waste

Including prions and destroying hazardous chemicals including formaldehyde and Chemotherapy drugs. More research is needed to validate its use for specific pharmaceuticals. It is cost competitive with incineration using air pollution control. Alkaline hydrolysis are marketed as tissue digesters for the destruction of human tissues and animal carcasses but can be used for either purpose. Unit capacities range from 10-15 kg to 4500kg per batch. The wastes are reacted with sodium or potassium hydroxide at around 110 to 130 degrees centigrade for around 3-8 hours depending on the system and the pressure at which it is operated.

Some alkaline hydrolysis units produce a solid residue that can be landfilled, others generate a liquid effluent. Liquid effluents will have a high organic load and high pH but can be discharged into a sewer after neutralization or dilution. Note: The story is collected for information purposes only for more information go through links provided in the sources.

References https://noharm-global.org/issues/global/treatingpharmaceutical-waste https://www.pharmatutor.org/articles/pharmaceuticalwate-management http://www.rroij.com/open-access/a-short-review-onpharmaceutical-waste-disposal-and-management.php?aid=82745

https://www.rdmag.com/article/2016/05/bestpractices-pharmaceutical-waste

Microbioz India, May 2019

Featured Article

The Asthma Diet: What you eat definitely makes a difference Ms. Pavithra N Raj, Chief Dietician, Columbia Asia Referral Hospital Yeshwanthpur Asthma is a chronic condition triggered by certain allergens that cause breathlessness, wheezing and coughing by affecting the lungs. This happens because when in contact with an allergen, the mucous membrane gets irritated and as a result, the airways swell up. Asthma is most often not treated as a critical affliction but doctors are of the opinion that it cannot only cause severe discomfort but can also be fatal. According to a study conducted by WHO, today, about 235 million people around the world suffer from asthma. There are two major causes of asthma: environmental and genetic. In Namma Bengaluru, it is the former that is wreaking havoc!

Turmeric: A pinch of turmeric boiled with milk and taken warm not only reduces inflammation in body, but also keeps the body hot from within.

Asthma triggers

Ghee: Ghee is rich with antioxidants and acts as an aid in the absorption of vitamins and minerals from other foods. It is good for skin and hair and is said to aid in tissue building process. Onions deep fried in ghee and mixed with pepper when taken hot cure cough.



Asthma triggers are different from person to person and can include:  Airborne substances, such as pollen, dust mites, mold spores, pet dander or particles of cockroach waste  Respiratory infections, such as the common cold  Physical activity (exercise-induced asthma)  Cold air  Air pollutants and irritants, such as smoke  Certain medications  Strong emotions and stress  Food additives A good diet is an important part to treat asthma. Just like regular workouts, a healthy diet is good for everyone. That goes for people with asthma, too. So here is the list of foods / food items which are the best and worst for asthma patients. Certain foods, such as milk, eggs, peanuts, soy, wheat, fish and shellfish, and food additives can trigger asthma symptoms. It is best to avoid these foods if they trigger an asthma attack.

Food to be consumed

Honey: Honey is considered warm. It contains small quantities of antigens found in flowers and helps in building up immunity. Protects from wheezing, coughing. Ginger: It contains antioxidants that help build strong resistance. If taken daily in small quantities, it not only keeps the body warm but also cures mild fever, acidity, common cold, cough and aids digestion.

Garlic: Garlic becomes an essential item to be included in food as it not only controls blood pressure and ensures proper flow of blood, but also keeps the body warm and energetic. Tulsi: Rich in vitamin A, C, calcium, zinc and iron, Tulsi helps body fight all cold borne diseases like cough, cold, sinusitis, pneumonia and all respiratory disorders. It is also a powerful antiseptic and anti-malarial agent. Taken raw with pepper and honey in empty stomach, it is an excellent remedy for cough and cold. Pepper: Pepper with its anti-oxidant and antibacterial properties is a must have. Besides keeping the body warm it also cures cold, cough and sinusitis. Saffron: Saffron or Kesari has been hailed as the source of beauty and health since times immemorial. When consumed with milk it increases body’s resistance and when mixed with cream and applied on face it makes skin clean, spotless and radiant.

Microbioz India, May 2019

Business News Nuts: Nuts are a natural source of anti-oxidants and are rich in vitamins and minerals. Powdered nuts taken with milk and honey is the best way to keep body warm from within.

Coffee: "Caffeine is a bronchodilator that may improve airflow. Black tea might be beneficial as well. Flax seeds: are high in omega-3 fatty acids as well as magnesium. Omega-3 have a beneficial effect on asthma.

Cipla receives final approval for generic version of Gilead Sciences, Inc’s Letairis® (Ambrisentan Tabs, 5mg & 10mg) Mumbai, India; April 30, 2019: – Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”) announce receipt of final approval for the Abbreviated New Drug Application (ANDA) for Ambrisentan Tablets 5mg & 10mg from the United States Food and Drug Administration (US FDA). Cipla’s Ambrisentan Tablets 5mg & 10mg is ABrated generic therapeutic equivalent version of

Gilead Sciences, Inc’s Letairis®. Ambrisentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening. The U.S. Sales of Letairis® Tablets USP stood at $943 million in 2018. The product is available for shipping immediately.

Lupin in alliance with Natco receives FDA approval for Bosentan Tablets Mumbai, Baltimore, April 30, 2019: Lupin Limited (Lupin) in alliance with Natco Pharma (Natco) announced that it has received approval for Bosentan Tablets, 62.5 mg and 125 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Actelion Pharmaceuticals Limited’s Tracleer Tablets, 62.5 mg and 125 mg. Lupin and Natco’s Bosentan Tablets, 62.5 mg and 125 mg, is the generic version of Actelion

Pharmaceuticals Limited’s Tracleer Tablets, 62.5 mg and 125 mg. It is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and to decrease clinical worsening. Bosentan Tablets, 62.5 mg and 125 mg had an annual sales of approximately USD 84.8 million in the US (IQVIA MAT March 2019).

Cipla launches Niveoli™, India’s first extra-fine ICS-LABA combination HFA inhaler Mumbai, April 12, 2019 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announces that it has launched Niveoli™, India’s first extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults,

targeting drug delivery to the small airways. Niveoli™ is a proprietary Cipla inhaler, and the latest offering from Cipla in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as

Microbioz India, May 2019

Business News asthma and chronic obstructive pulmonary disorder (COPD). Asthma and COPD are lung conditions that affect the ability to breathe. Extensive research and an evolved understanding of the diseases over the years has shown the significant role of small airway disease in asthma and COPD. A recent metaanalysis showed that small airway disease is prevalent in 5060% of asthma patients[1]. Another study has indicated that routine lung function tests can underestimate problems in the small airways [2]. Small airway disease is a common feature of COPD and gets worse with increasing severity of the condition[3]. Niveoli™’s novelty and strength lies in HFA propelled delivery of extra-fine particles of beclomethasone, an inhaled corticosteroid (ICS) and formoterol, a fast-onset long acting beta agonist (LABA) to the small airways. [1] Respir Med 2016; 116: 19-27 [2] Respir Med 2013; 107: 1667-1674 [3] Am J Respir Crit Care Med 2016; 194: 178-184[1] Respir Med 2016; 116: 19-27

Commenting on the launch, Nikhil Chopra, Head – India business, Cipla, said, “Cipla is pleased to offer yet another milestone in respiratory inhalation therapy. Niveoli™ marks a first in

acknowledging and addressing the issue of drug delivery to the small airways. Cipla has a long history of blazing the trail in innovations in combination formulations and drug-device combinations in the respiratory therapy, and Niveoli™ is a painstaking result of

these strengths. Be it the transparent dry powder inhaler, the static-free spacer with valve mechanism, the mask-spacer combination for children or our novel breath-actuated inhaler with dose counter called Synchrobreathe™, the list is long. We see our market leadership as well as the range and depth of our R&D and manufacturing capabilities in this therapy as a privilege and a responsibility to do more for patients. In keeping with our purpose of ‘Caring for Life’, we are constantly studying OADs and working towards products that offer greater efficacy, ease of use and drug delivery to patients. I believe Niveoli™ represents a new paradigm in inhalation therapy.”

Microbioz India, May 2019

Research News

Researchers identify faster, more effective drug combinations to treat tuberculosis Tuberculosis is a potentially deadly though curable disease. Each year about 10 million people develop active cases, and 1.6 million people die. In addition, about 1.7 billion people around the world are infected with TB bacteria, which can lie dormant for weeks to years, then become active and cause disease in up to 10 percent of those who are infected. Today, people who contract tuberculosis typically take a course of drugs for six to eight months. However, the length of treatment means some patients don't stick with the therapy or may develop adverse effects from drug toxicity. Some may develop resistance to the drugs, requiring changes in the drug regimen that can lengthen the treatment to as long as two years. Even worse, there is a high fatality rate among those with drugresistant TB. In new research, UCLA scientists have reported finding a way to significantly reduce the duration of treatment by using an approach called "artificial intelligence-parabolic response surface." This data analysis method identifies which drug combinations work synergistically -- that is, individual drugs working together in a way that is more potent than the sum of their individual potencies. The method, when used in cell culture and subsequently mouse models of TB, allowed researchers to quickly identify three- or four-drug combinations among billions of possible combinations of drugs and doses, that significantly cut the duration of TB therapy. These regimens are suitable for treating both drug-sensitive TB and most cases of drug-resistant TB -- that is, they are "universal" regimens -- and are up to five times faster than the currently available standard treatment. "If our findings are replicated in human studies, patients will be cured much faster, be more likely to adhere to the drug regimen, suffer less drug toxicity, and be less likely to develop drug-resistant TB," said Dr. Marcus Horwitz, distinguished professor of medicine and microbiology, immunology & molecular genetics at the David Geffen School of Medicine at UCLA, and the study's senior author.

The study is published in the peer-reviewed PLOS One. The artificial intelligence-parabolic response surface platform was developed by co-author Chih-Ming Ho, distinguished research professor of mechanical and aerospace engineering at the UCLA Henry Samueli School of Engineering. The platform has been applied to infectious diseases, cancers and organ transplants. In all, the researchers evaluated 15 drugs to identify the best four-drug combinations. The two most potent regimens comprised clofazimine, bedaquiline, pyrazinamide, and either amoxicillin/clavulanate or delamanid. Two of the drug regimens achieved a 100 percent cure rate, without relapse, in mice in three weeks. Another regimen cured the mice in five weeks. Both of the drug combinations included currently approved medications, Horwitz said. Mice who were treated with a standard drug therapy all still had TB bacteria in their lungs after six weeks, and in companion studies, these mice required 16 to 20 weeks to achieve a 100 percent relapse-free cure. The next step will be to test the drug regimens in humans with tuberculosis who are resistant to the standard drugs used to treat TB. The researchers also plan to Foundation. Story Source: Materials provided by University of California Los Angeles Health Sciences. expand the therapy platform to include experimental TB drugs to develop even more potent combinations. The study was supported by a subgrant from Shanghai Jiao Tong University, a grantee of the Bill & Melinda Gates Note: Content may be edited for style and length. Journal Reference: Daniel L. Clemens, Bai-Yu Lee, Aleidy Silva, Barbara Jane Dillon, SaĹĄa MasleĹĄa-GaliÄ&#x2021;, Susana Nava, Xianting Ding, Chih-Ming Ho, Marcus A. Horwitz. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. PLOS ONE, 2019; 14 (5): e0215607 DOI: 10.1371/journal.pone.0215607

Microbioz India, May 2019

Product Launches

Highly Effective Protein Clean-Up Microplate

Verifiable 2D Coded Tube Selection from Racks

The Protein Crash technique used by the Porvair Sciences P3 microplate is highly effective at removing proteins from biological samples prior to analysis.

Ziath has announced a unique combination of instruments that ensures the correct 2D coded tubes are automatically withdrawn from storage racks without the huge expense of a fully-robotic tube picking system.

The P3 microplate works by denaturing the protein upon addition of solvents such as acetonitrile or methanol. The proteins â&#x20AC;&#x153;crashâ&#x20AC;? or precipitate out of solution to forms large sticky globules that are then trapped on an open-pore structure filter. Underneath this filter is a highly hydrophobic filter which retains all liquids above it. When a vacuum is applied to the P3 microplate, the liquid containing the analytes of interest is efficiently drawn through the filter and into a collection plate below leaving behind unwanted proteins that can interfere with downstream applications. The novel dual filter technology in the P3 microplate not only retains unwanted proteins and has good flow rates, it ensure no leakage occurs prior to collection by vacuum. Designed and precision manufactured to conform with ANSI /SLAS guidelines - the automation-friendly P3 microplate enables 96 samples to be filtered simultaneously â&#x20AC;&#x201C; accelerating your biological sample clean-up prior to analysis. The P3 microplate is manufactured from specially selected polypropylene to ensure very low extractables. The dual filters in the P3 plate are produced from an inert material to ensure no adsorption of components from your biological samples thereby eliminating the chance of cross contamination or loss of sample integrity.

The story source and credit: Porvair Sciences Limited

The Mohawk tube selector from Ziath is a costeffective semi-automated unit for selecting 2D-bar coded tubes from their storage racks, an ideal solution for many medium-throughput applications such as compound management and biobanking. The real power of the new Ziath solution comes from the built-in operational verification and tractability afforded by linking a Ziath CMOScamera-based scanner directly to the Mohawk picker. The control interface software allows a rack of tubes to be scanned and decoded so that tubes to be picked by the Mohawk can be identified by their individual bar codes. Once the Mohawk has ejected the tubes from their parent racks, a daughter rack can be assembled manually. This is then verified on the same scanner to ensure that only the correct tubes have been selected from the parent rack(s). Alternatively, the Mohawk tube selector software can use an imported pick list, generated in an Excel spreadsheet, LIMS or inventory management program, to select which tubes to pick. As before, the daughter rack(s) can then be verified on the connected Ziath scanner.

Microbioz India, May 2019

Product Launches Using the powerful combination of the Mohawk semi-automated tube selector with a Ziath Cube, Express or Mirage scanner enables verifiable tube selection for the creation of daughter sample sub-sets both quickly and easily with full tractability throughout.

The story source and credit: Ziath

Bio-Rad Introduces Isotype-Specific Secondary Antibodies Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, announce the launch of its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the three main mouse isotypes: IgG1, IgG2a, and IgG2b, offer improved signal detection and specificity in imaging, ELISA, flow cytometry, and western blotting.

Secondary antibodies are key components of antibody detection systems. The selection of an optimum secondary antibody can improve positive signals in addition to reducing false positive or negative staining. Recombinant monoclonal isotypespecific secondary antibodies detect individual isotypes, without species or isotype cross-reactivity, enabling multiple unlabeled mouse monoclonal antibodies of differing isotypes to be used simultaneously. This obviates the need to source secondary antibodies from other species. The isotype-specific antibodies offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required, for instance, during multiplexing or to prevent nonspecific background staining. Bio-Rad’s recombinant monoclonal antibodies are generated using the Human Combinatorial Antibody

Library (HuCAL®) and CysDisplay®, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures consistent and secure supply. “Recombinant human monoclonal antibodies are selected against epitopes unique to the isotype and offer significant advantages over traditional secondary antibodies,” said Tracey Long, Bio-Rad Marketing Manager, Life Science Group. “Bio-Rad’s recombinant monoclonal isotype-specific antibodies are easy to use and can be substituted for any secondary in the protocol without the need for extra steps," she added.

The story source and credit: Bio-Rad Laboratories

Hitachi HighTechnologies Launches Two New Scanning Electron Microscopes Hitachi High-Technologies is set to launch two new scanning electron microscopes (SEMs), which will be unveiled at the 33rd Control in Stuttgart, Germany, between the 7th and 10th May.

The SU3800 and oversized SU3900 SEMs feature the ability to accommodate large, heavy specimens, along with advanced functionalities for automated measurement and wide-angle camera navigation. SEMs perform a diverse array of structural observations and compositional analyses in a wide variety of fields, including nanotechnology and biotechnology. Dr Robert Steffen, European product manager at Hitachi High-Technologies Europe, said: “SEM applications are expanding more rapidly than ever,

Microbioz India, May 2019

Product Launches requiring analysis of greater size and weight specimens, such as materials from mining or automotive-related industries. However, specimens of this nature push stage limits beyond previous capacity, making it necessary to cut or further process before imaging – this restriction has given rise to demand for the ability to observe samples without reducing the size. “Furthermore, SEMs are increasingly a key component for quality assurance and production control, in addition to their conventional applications in research and development. As a result, modern SEMs must be highly versatile and easy to use for all experience levels.” To address these needs and more, Hitachi HighTechnologies has introduced a novel solution with the SU3800/SU3900. Advanced automation functions, including auto-start, wide-angle camera navigation with stitching and auto-algorithms, enable a high-throughput, easy-to-use system for both new and experienced operators. The oversized SU3900 features a class-leading specimen chamber/stage configuration with ability to accommodate a 300mm sample diameter and loading capacity of up to 5kg. This allows for easy observation of very large samples without the need to cut or process prior to imaging.

Introducing the NanoScanOP 400 Nanopositioning Piezo Objective Scanner from Queensgate/Prior Scientific The NanoScanOP 400 provides the fastest step and settle time of any objective positioner available. Incorporating capacitive feedback sensors, it also has market leading positioning accuracy and resolution. Compatible with most microscopes and objective lenses, the system has settings optimized for different objective sizes, weights and performance requirements. The user simply selects the best setting for their application.

Robert added: “The development of the SU3800/SU3900 marks another key step in the development of Hitachi High-Technologies’ SEMs, and their applications within the field of microscopy. “The improvements in the specimen chamber size means that there is no longer the need to cut or further process a sample before imaging, which in turn provides a truer, more accurate image of the sample. As a result, users can cut down processing time and improve efficiencies within their business. “At Hitachi High-Technologies, our aim is to offer customers products that meets their ever-evolving requirements. Therefore, we will continue to promote development, as well as sales expansion of highly sophisticated solutions and technologies, by responding swiftly to the needs of customers and markets.”

The story source and credit: Technologies

Hitachi High-

Key Features of the NanoScanOP 400  



400μm closed loop travel range (450μm open loop) Connectors with built in stage calibration provide plug and play electronics which can be interchanged, minimizing system down times. Made from stainless steel - providing greater mechanical stiffness (faster) and temperature stability (lowest drift). The stage is a flexure guided system. The friction free flexures are designed to provide high stiffness and to minimize off axis motions giving high repeatability and faster cycle times.

Microbioz India, May 2019

Product Launches 

Suitable for applications.

upright

and

inverted

Applications for the NanoScanOP 400      

Optical sectioning producing 3D images Autofocus systems for time-lapse imaging High content screening Surface analysis Semiconductor wafer inspection Scanning interferometry

High Performance MALS Detector Enables Advanced Characterization The PN3621 Multi-Angle Light Scattering (MALS) detector from Postnova Analytics combines outstanding performance, high precision, ease of use and reliability to enable customers to readily achieve advanced characterization of proteins, conjugates, macromolecules, and nanoparticles.

The PN3621 is commonly used in conjunction with Gel Permeation Chromatography (GPC-MALS), Size Exclusion Chromatography (SEC-MALS) or FieldFlow Fractionation (FFF-MALS) to determine distributions of mass, size and composition independent of column calibration by reference standards. Learn more about the NanoScanOP Nanopositioning Piezo Objective Scanner

The story source and credit: Technologies

400

Hitachi High-

Designed for many years of reliable, trouble-free operation the customer-friendly PN3621 incorporates a unique vertical ‘clean by design’ flow cell. Unlike MALS instruments with problem prone horizontal flow cells, the vertical cell design 'selfcleans' and also enables large and potentially fragile high molar mass macromolecules to pass through unaltered. Incorporating the widest range of working angles in a commercially available light scattering detector (7°164°) the PN3621 MALS ensures unmatched precision in molecular weight and molecular or particle size determination. Employing 21 angles of light scattering detection enables the PN3621 to achieve better results than any other MALS detector, especially with complex or high molar mass polymers, particles and protein aggregates. Angles below 35° are crucial for precise molar mass and size

Microbioz India, May 2019

Product Launches determination. For this application the PN3621 MALS offers a complete set of stable and sensitive low angle detectors at 7°, 12°, 20° and 28°. This outstanding low angle light scattering capability, coupled with high sensitivity, results in high data quality in all applications. The PN3621 comes with highly intuitive, yet powerful software enabling comprehensive analysis

of and reporting on light scattering results. The PN3621 is very compact and lightweight saving valuable laboratory space and enabling you to easily transport and use the detector in different locations.

The story source and credit: Postnova Analytics GmbH

Radio-opaque silicone tube by Amipolymer Pvt ltd Now a day silicone based biocompatible Polymers are used to produce catheters and other devices that are inserted into the body for interventional procedures. Part inserted are commonly filled with substances opaque to x-rays, thereby rendering the devices visible under fluoroscopy or x-ray imaging. These fillers, or radiopacifiers are based on typically dense metal or metallic salt powders affect the energy attenuation of photons in an xray beam as it passes through matter, reducing the intensity of the photons by absorbing or defecting them. Because these materials exhibit a higher attenuation coefficient than soft tissue or bone, they appear lighter on a fluoroscope or x-ray film. This visibility provides idea about accurately position the device in the affected area. Image contrast and sharpness can be varied by the type and amount of radio pacifier used. Device design is also a factor like a higher loading of radiopaque material, for instance, is needed for thin-wall catheter tubing than for products with thicker walls. Generally, compounds should contain only the amount of additives absolutely required for the application, since overloading can result in the loss of the polymer's mechanical properties. Blending together several radiopaque materials can produce better results than using only one type in a formulation. Among the most widely used radio pacifiers for medical devices are barium sulfate, bismuth compounds, and tungsten metals that are excellent absorbers of x-rays. Selection of the correct fillers in the proper amount requires a thorough understanding of attenuation and how it is affected by various radiopaque compounds.

0.1 Å. X-rays are produced from the conversion of energy that results when fast-moving electrons from the element of an x-ray tube interact with a tungsten anode or target. The kinetic energy of the electrons increases as voltage (Kvp). The intensity of an x-ray beam is determined by the number of photons in the beam and the energy of the photons in terms of Kev. Material: Barium Sulfate. Barium sulfate (BaSO4) was the first radiopaque material to be widely compounded in medical formulations and is the most common filler used with medical-grade polymers. It is a non-harmful filler having specific gravity of 4.5. For optimize X-ray imaging during interventional procedure normal doses are 20 to 40 PHR. Higher doses might be destroy base polymer physical properties. Bismuth. Considerably more expensive than barium. Bismuth trioxide (Bi2O3), which is yellow in color, has a specific gravity of 8.9. Since bismuth produces a brighter, sharper, highercontrast image on an x-ray film than does barium, it is commonly used where a high level of radiopacity is required. Tungsten. It is a fine metal powder with a specific gravity of 19.35. Tungsten (W) is more than twice as dense as bismuth and can provide a high attenuation coefficient. Higher level of loading is possible up to 60% for better attenuation and image contrast but beyond that surface roughness is taken place.

X-rays are belonging from electromagnetic radiations family having a range of wavelengths. Diagnostic x-rays fall near the shorter-wavelength end of the spectrum, measuring between 1 Å and

Figure 1 Characteristics X-Ray generation

Microbioz India, May 2019

Product Launches

Figure 3 X-Ray Radiology

Medical devices used in diagnostic radiology must be easily seen on x-ray film and fluoroscopes in order for medical practitioners to precisely position them inside the body during critical procedures. The type and amount of radiopaque filler Compounded with silicone

Figure 2 Radiopaque catheter for interventional procedure

elastomer in the manufacture of these devices determines how they appear. By: Pritam Adhikary (Executive-R&D) Ami Polymer Pvt. Ltd. # +91 82389 22236

research@amipolymer.com

Cold chamber by mack Pharmatech Pvt ltd Mack Pharmatech offers cost effective PLC based Cold chambers with European standard “CE” in different capacities. Our Cold Chambers have Temperature Range: 2°C to 8°C, Accuracy : ± 1.5°C , Uniformity: ± 2°C Control System: PLC (Allen Bradley)

Mack Pharmatech is the only company who gives all equipment with PLC Based Control System,

Microbioz India, May 2019

Product Launches 21 CFR Software, HMI (Touch Screen Display), Stand By Refrigeration System, GSM Technology, Hooter System, GMP Model, Full View Glass Door, Bullet feet leveling legs Tray Spacing every ½ “Adjustable and many more features.

For more information: Mack Pharmatech Pvt ltd Corporate / Factory Office: B-48, Malegaon MIDC, Sinnar, Dist.-Nasik, Maharashtra 422 113, INDIA Mobile: +91 93259 65656 Telefax: +91-02551-230877 URL: www.mackpharmatech.com E-Mail: sales@mackpharmatech.com

Expanded program with Baths and Circulators Baths and circulation thermostats for temperatures from -90 to +300 °C / as a standard with natural refrigerants Huber Kältemaschinenbau has further expanded its range of classic heating and cooling thermostats. The

The product line also includes the smallest cooling thermostats in the world, the Ministats. CC models and Ministats are equipped with a Pilot ONE touchscreen controller, which offers a 5.7” TFT color display as well as USB and LAN ports. Additional features include adjustable pumping capacity, sensor calibration, clock function, auto start, a Favorites menu and convenient menu navigation in 11 languages. Another advantage is the electronic upgrade feature - it enables the activation of additional functions such as programmer or process control. In contrast, the KISS models focus on basics. These devices are inexpensive and are recommended for many routine tasks. These devices have an OLED temperature display and protection functions according to Class III/FL (DIN 12876). Both model ranges are available with polycarbonate or stainless steel baths. The cooling thermostats operate environmentally friendly and use natural refrigerants. For more information or to request the current catalog call us at +49 (0) 781 9603-0.

program offers two product lines: While the CC models meet the highest standards, the KISS models stand for simple operation and affordable prices. The product range include immersion circulators, baths and circulation thermostats for temperatures from 90 to +300 °C.

The story source and credit: Huber

Microbioz India, May 2019

PUBLISHED ON: 20th May 2019

RNI NUMBER: UPENG/2017/73675